None listed
Conditions
Interventions
Single intake of active food 1
Single intake of active food 2
Single intake of Placebo food
Sponsors
Meiji Co., Ltd.
Otsuma Women'
s University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Healthy adults range in age from 18 to 65 at the time of informed consent 2. Subjects whose defecation frequency are more than 3 times a week 3. Subjects with a BMI of 18.5 or more and less than 25 4. Subjects who agree to participate in this study with a written informed consent after receiving sufficient explanation relating to this study
Exclusion criteria
Exclusion criteria: 1. Subjects with food allergies 2. Subjects who suffer from serious disorders of liver, kidney, heart, lung, digestive organs, diabetes, rheumatoid arthritis, neurological/mental diseases, endocrine diseases, or other serious and/or progressive diseases 3. Subjects with a history of stomach, small intestine, or large intestine resection (including appendectomy and colonoscopy) 4. Heavy drinkers (weekly average of 50 g / day or more of pure alcohol) 5. Smoker 6. Subjects who regularly take supplements and health foods for intestinal function or containing prebiotics (e.g. Oligosaccharide, dietary fiber) (Continuing for 2weeks or more at a frequency of 3 or more days a week) 7. Subjects who have a habit of skipping meals (missing meals for 4 or more days a week) 8. Subjects who using blood glucose regulating medications (e.g. hypoglycemic drug, insulin and so on) 9. Subjects who have taken drugs containing antibiotics within the past 4 weeks 10. Subjects who are currently taking oral drug for hay fever and subjects who may be taking it during the study period (However, users who only use nasal sprays and eye drops are not excluded) 11. Subjects who are currently pregnant or breastfeeding, or who wish to become pregnant during the test period. 12. Subjects who donated more than 200ml blood within the past 1 month 13. Subjects who participate in other clinical trials within the past 3 months or have plans to participate in other clinical trials during this study period 14. Subjects who determine ineligible by the principal investigator or the co-investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood glucose concentration | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood GLP-1 concentration (Blood Glucagon-like peptide-1 concentration), VAS (Hunger, Fullness, Desire-to-eat, Prospective Food Consumption, Thirst, Comfort), Blood Insulin concentration, Breath hydrogen concentrations | — |
Countries
Japan
Contacts
Public ContactAtsumi Miyagawa
Meiji Co., Ltd. R&D Division
Outcome results
None listed